OmniCyte
- Biotech or pharma, therapeutic R&D
Omnicyte has developed an immuno-oncology platform technology that selectively activates the innate and adaptive cancer immune system to infiltrate and kill tumors. 1st indication is ovarian cancer, however we can engineer our therapeutic for other tumors
Address
New YorkCT
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}